Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TransCode Therapeutics ( (RNAZ) ) just unveiled an update.
On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of Functional Biomaterials of preclinical data showing that its lead RNA-based candidate TTX-MC138 successfully targeted glioblastoma multiforme tumors in murine models, delivered antisense oligonucleotides systemically to brain tumors, suppressed the miR-10b target, increased apoptotic activity and significantly extended survival. The findings, generated in collaboration with Michigan State University, underscore the potential of TransCode’s TTX delivery platform to overcome key barriers to nucleic acid delivery in brain cancers, complement existing IND-enabling, pharmacokinetic, biodistribution and toxicity work already completed for TTX-MC138, and strengthen the rationale for advancing the candidate from its current Phase 1a testing in metastatic disease toward future clinical evaluation in glioblastoma, with a Phase 2a trial in metastatic indications planned for the first half of 2026.
The most recent analyst rating on (RNAZ) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate events around clinical progress and financing provide partial offset, while valuation support remains limited due to ongoing losses and no dividend.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company focused on immuno-oncology and RNA therapeutics for the treatment of high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, and the company maintains a broader portfolio of first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
Average Trading Volume: 151,995
Technical Sentiment Signal: Sell
Current Market Cap: $6.7M
Find detailed analytics on RNAZ stock on TipRanks’ Stock Analysis page.